{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T12:50:38Z","timestamp":1787143838238,"version":"build-2736575974"},"reference-count":40,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"DOD TVA W81XWH-12-1-0447","doi-asserted-by":"publisher","award":["BC111085"],"award-info":[{"award-number":["BC111085"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Ductal carcinoma in situ (DCIS) of the breast is often managed by lumpectomy and radiation or mastectomy, despite its indolent features. Effective non-invasive treatment strategies could reduce the morbidity of DCIS treatment. We have exploited the high heat shock protein 90 (HSP90) activity in premalignant and malignant breast disease to non-invasively detect and selectively ablate tumors using photodynamic therapy (PDT). PDT with the HSP90-targeting photosensitizer, HS201, can not only ablate invasive breast cancers (BCs) while sparing non-tumor tissue, but also induce antitumor immunity. We hypothesized that HS201-PDT would both non-invasively ablate DCIS and prevent progression to invasive BC. We tested in vitro selective uptake and photosensitivity of HS201 in DCIS cell lines compared to the non-selective parental verteporfin, and assessed in vivo antitumor efficacy in mammary fat pad and intraductal implantation models. Selective uptake of HS201 enabled treatment of intraductal lesions while minimizing toxicity to non-tumor tissue. The in vivo activity of HS201-PDT was also tested in female MMTV-neu mice prior to the development of spontaneous invasive BC. Mice aged 5 months were administered HS201, and their mammary glands were exposed to laser light. HS201-PDT delayed the emergence of invasive BC, significantly prolonged disease-free survival (DFS) (p = 0.0328) and tended to improve overall survival compared to the no-treatment control (p = 0.0872). Systemic administration of anti-PD-L1 was combined with HS201-PDT and was tested in a more aggressive spontaneous tumor model, HER2delta16 transgenic mice. A single PDT dose combined with anti-PD-L1 improved DFS compared to the no-treatment control, which was significantly improved with repetitive HS201-PDT given with anti-PD-L1 (p = 0.0319). In conclusion, a non-invasive, skin- and tissue-sparing PDT strategy in combination with anti-PD-L1 antibodies effectively prevented malignant progression of DCIS to invasive BC. This non-invasive treatment strategy of DCIS may be safe and effective, while providing an option to reduce the morbidity of current conventional treatment for patients with DCIS. Clinical testing of HS201 is currently underway.<\/jats:p>","DOI":"10.3390\/cancers14235762","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T02:54:05Z","timestamp":1669258445000},"page":"5762","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Non-Invasive Deep Photoablation Technique to Inhibit DCIS Progression and Induce Antitumor Immunity"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0510-4602","authenticated-orcid":false,"given":"Kensuke","family":"Kaneko","sequence":"first","affiliation":[{"name":"Department of Surgery, Duke University Medical Center, 203 Research Drive, Rm 433A Box 2606, Durham, NC 27710, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nagata","sequence":"additional","affiliation":[{"name":"Department of Surgery, Duke University Medical Center, 203 Research Drive, Rm 433A Box 2606, Durham, NC 27710, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yi","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Surgery, Duke University Medical Center, 203 Research Drive, Rm 433A Box 2606, Durham, NC 27710, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5635-7314","authenticated-orcid":false,"given":"Joshua","family":"Ginzel","sequence":"additional","affiliation":[{"name":"Department of Cell Biology, Duke University School of Medicine, Durham, NC 27710, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Hartman","sequence":"additional","affiliation":[{"name":"Department of Surgery, Duke University Medical Center, 203 Research Drive, Rm 433A Box 2606, Durham, NC 27710, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0273-6284","authenticated-orcid":false,"given":"Jeffrey","family":"Everitt","sequence":"additional","affiliation":[{"name":"Department of Pathology, Duke University School of Medicine, Durham, NC 27710, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2217-455X","authenticated-orcid":false,"given":"Philip","family":"Hughes","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Haystead","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5725-4533","authenticated-orcid":false,"given":"Michael","family":"Morse","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0063-4770","authenticated-orcid":false,"given":"Herbert Kim","family":"Lyerly","sequence":"additional","affiliation":[{"name":"Department of Surgery, Duke University Medical Center, 203 Research Drive, Rm 433A Box 2606, Durham, NC 27710, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1424-5001","authenticated-orcid":false,"given":"Takuya","family":"Osada","sequence":"additional","affiliation":[{"name":"Department of Surgery, Duke University Medical Center, 203 Research Drive, Rm 433A Box 2606, Durham, NC 27710, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/jnci\/djv263","article-title":"Trends in treatment patterns and outcomes for ductal carcinoma in situ","volume":"107","author":"Worni","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/cncr.20979","article-title":"Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: Results from the Nurses\u2019 health study","volume":"103","author":"Collins","year":"2005","journal-title":"Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/1097-0142(19820215)49:4<751::AID-CNCR2820490426>3.0.CO;2-Y","article-title":"Intraductal carcinoma of the breast: Follow-up after biopsy only","volume":"49","author":"Page","year":"1982","journal-title":"Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1002\/cncr.21069","article-title":"The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow up","volume":"103","author":"Sanders","year":"2005","journal-title":"Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/bcr1346","article-title":"Overdiagnosis and overtreatment of breast cancer: Rates of ductal carcinoma in situ: A US perspective","volume":"7","author":"Kumar","year":"2005","journal-title":"Breast Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.7326\/0003-4819-127-11-199712010-00014","article-title":"Using autopsy series to estimate the disease \u2018\u2018reservoir\u2019\u2019 for ductal carcinoma in situ of the breast: How much more breast cancer can we find?","volume":"127","author":"Welch","year":"1997","journal-title":"Ann. Intern. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.ajpath.2018.08.020","article-title":"Ductal Carcinoma in Situ Biomarkers in a Precision Medicine Era: Current and Future Molecular-Based Testing","volume":"189","author":"Shee","year":"2019","journal-title":"Am. J. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/jnci\/85.6.443","article-title":"Photodynamic therapy in oncology: Mechanisms and clinical use","volume":"85","author":"Pass","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nrc1071","article-title":"Photodynamic therapy for cancer","volume":"3","author":"Dolmans","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/153303460800700405","article-title":"Photodynamic therapy for treatment of solid tumors--potential and technical challenges","volume":"7","author":"Huang","year":"2008","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.3390\/ph3051507","article-title":"Targeted Therapy of Cancer Using Photodynamic Therapy in Combination with Multi-faceted Anti-Tumor Modalities","volume":"3","author":"Olivo","year":"2010","journal-title":"Pharmaceuticals"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/s42003-020-0956-7","article-title":"Heat shock protein 90-targeted photodynamic therapy enables treatment of subcutaneous and visceral tumors","volume":"3","author":"Kaneko","year":"2020","journal-title":"Commun. Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"004793","DOI":"10.1136\/jitc-2022-004793","article-title":"A combination of a novel heat shock protein 90-targeted photodynamic therapy with PD-1\/PD-L1 blockade induces potent systemic antitumor efficacy and abscopal effect against breast cancers","volume":"10","author":"Kaneko","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"7531","DOI":"10.1158\/1078-0432.CCR-17-1453","article-title":"In Vivo Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior","volume":"23","author":"Osada","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1021\/acschembio.7b00006","article-title":"A Fluorescent Hsp90 Probe Demonstrates the Unique Association between Extracellular Hsp90 and Malignancy in Vivo","volume":"12","author":"Crowe","year":"2017","journal-title":"ACS Chem. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.chembiol.2013.08.004","article-title":"Optical and radioiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells","volume":"20","author":"Barrott","year":"2013","journal-title":"Chem. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.4161\/cbt.8.20.9639","article-title":"Elevated expression of nuclear Hsp90 in invasive breast tumors","volume":"8","author":"Diehl","year":"2009","journal-title":"Cancer Biol. Ther."},{"key":"ref_18","first-page":"6740","article-title":"Proteomics of human breast ductal carcinoma in situ","volume":"62","author":"Wulfkuhle","year":"2002","journal-title":"Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): A randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for Early Triple-Negative Breast Cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"724424","DOI":"10.3389\/fonc.2021.724424","article-title":"Clinical progress of PD-1\/L1 inhibitors in breast cancer immunotherapy","volume":"11","author":"Chen","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"003717","DOI":"10.1136\/jitc-2021-003717","article-title":"Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity","volume":"10","author":"Abe","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1158\/1078-0432.CCR-13-2267","article-title":"PI3K Pathway Activation in High-Grade Ductal Carcinoma In Situ\u2014Implications for Progression to Invasive Breast Carcinoma","volume":"20","author":"Sakr","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.celrep.2016.06.051","article-title":"Molecular Features of Subtype-Specific Progression from Ductal Carcinoma In Situ to Invasive Breast Cancer","volume":"16","author":"Lesurf","year":"2016","journal-title":"Cell Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/modpathol.2017.21","article-title":"Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer","volume":"30","author":"Pang","year":"2017","journal-title":"Mod. Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41523-021-00267-z","article-title":"Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection","volume":"7","author":"Glencer","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1002\/ijc.22572","article-title":"Dynamic stromal-epithelial interactions during progression of MCF10DCIS.com xenografts","volume":"120","author":"Tait","year":"2007","journal-title":"Int. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ccr.2006.10.008","article-title":"A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes","volume":"10","author":"Neve","year":"2006","journal-title":"Cancer Cell"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/bcr2358","article-title":"An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ","volume":"11","author":"Behbod","year":"2009","journal-title":"Breast Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1023\/A:1018712905244","article-title":"The Comparative Pathology of Human and Mouse Mammary Glands","volume":"4","author":"Cardiff","year":"1999","journal-title":"J. Mammary Gland. Biol. Neoplasia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4670","DOI":"10.1158\/1078-0432.CCR-20-0389","article-title":"Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and \u03b1PD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer","volume":"26","author":"Crosby","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6053","DOI":"10.1038\/onc.2016.129","article-title":"The ErbB2\u0394Ex16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment","volume":"35","author":"Turpin","year":"2016","journal-title":"Oncogene"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamaoncol.2015.2510","article-title":"Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ","volume":"1","author":"Narod","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10549-005-9101-z","article-title":"The natural history of ductal carcinoma in situ of the breast: A review","volume":"97","author":"Erbas","year":"2006","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/cncr.20260","article-title":"The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: A study of a large cohort of patients treated with surgery alone","volume":"100","author":"Cornfield","year":"2004","journal-title":"Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/00130404-200501000-00012","article-title":"Ablative approaches to the minimally invasive treatment of breast cancer","volume":"11","author":"Agnese","year":"2005","journal-title":"Cancer J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.clbc.2021.03.004","article-title":"Thermal Ablation as an Alternative for Surgical Resection of Small (\u22642 cm) Breast Cancers: A Meta-Analysis","volume":"21","author":"Struik","year":"2021","journal-title":"Clin. Breast Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Banerjee, S.M., El-Sheikh, S., Malhotra, A., Mosse, C.A., Parker, S., Williams, N.R., MacRobert, A.J., Hamoudi, R., Bown, S.G., and Keshtgar, M.R. (2020). Photodynamic Therapy in Primary Breast Cancer. J. Clin. Med., 9.","DOI":"10.3390\/jcm9020483"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/bcr3168","article-title":"Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer","volume":"14","author":"Cheng","year":"2012","journal-title":"Breast Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc1716","article-title":"HSP90 and the chaperoning of cancer","volume":"5","author":"Whitesell","year":"2005","journal-title":"Nat. Rev. Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/23\/5762\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:25:07Z","timestamp":1760145907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/23\/5762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,23]]},"references-count":40,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["cancers14235762"],"URL":"https:\/\/doi.org\/10.3390\/cancers14235762","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,23]]}}}